AR045389A1 - Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido - Google Patents

Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido

Info

Publication number
AR045389A1
AR045389A1 ARP040103010A ARP040103010A AR045389A1 AR 045389 A1 AR045389 A1 AR 045389A1 AR P040103010 A ARP040103010 A AR P040103010A AR P040103010 A ARP040103010 A AR P040103010A AR 045389 A1 AR045389 A1 AR 045389A1
Authority
AR
Argentina
Prior art keywords
alkyl
cyclyl
optionally substituted
heterocyclyl
alkoxy
Prior art date
Application number
ARP040103010A
Other languages
English (en)
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AR045389A1 publication Critical patent/AR045389A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo N-sustituido, composiciones farmacéuticas que los comprenden y usos. Reivindicación 1: un compuesto representado por la fórmula (1) o una sal o N-óxido farmacéuticamente aceptable del mismo, en donde R11 es F, Cl, alquilo C0-8, alcoxi C0-8, o -N(alquilo C0-8)(alquilo C0-8); R51 es fenilo, opcionalmente sustituido con 1-5 sustituyentes independientes; halógeno, NR34R35, -NR34COR35, -NR34C(O)OR35, -NR34SO2R35, -OR34, -SR34, -SO2R34, -SO2NR34R35, -C(O)OR34, -CO2H, -CONR34R35, alquilo C0-8, alquenilo C2-8, alquinilo C2-8, CN, CF3, NO2, oxo, ciclilo o heterociclilo; r52 es halógeno, CF3, -CN, alquilo C0-8, alcoxi C0-8, -COOH, o -N(alquil C0-8)(alquiloC0-8); X es un grupo ciclilo o heterociclilo, opcionalmente sustituido con 1-4 sustituyentes independientes: F, Cl. CF3, -CN, alquilo C0-8, alcoxi C0-8, -COOH, o -N(alquil C0-8)(alquilo C0-8); R34 y R35 son independientemente alquilo C0-8 opcionalmente sustituido con un sustituyentes heterociclilo u OH; -alquilo C0-8-cicloalquilo C3-8, CF3, -alquilo C0-8-O-alquilo C0-8, -alquilo C0-8-N(alquilo C08-)(alquiloC0-8), -alquilo C0-8-s(O)0-2-alquilo C0-8; o heterociclilo opcionalmente sustituido con alquilo C0-8, ciclilo o sustituyente ciclilo sustituido.
ARP040103010A 2003-08-21 2004-08-20 Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido AR045389A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49676603P 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
AR045389A1 true AR045389A1 (es) 2005-10-26

Family

ID=34272512

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP040103010A AR045389A1 (es) 2003-08-21 2004-08-20 Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido

Country Status (19)

Country Link
EP (1) EP1664032B1 (es)
JP (1) JP4795237B2 (es)
KR (1) KR20060115346A (es)
CN (1) CN1839130A (es)
AP (1) AP2006003553A0 (es)
AR (1) AR045389A1 (es)
AT (1) ATE413395T1 (es)
AU (1) AU2004268948A1 (es)
BR (1) BRPI0413785A (es)
CA (1) CA2536151A1 (es)
DE (1) DE602004017623D1 (es)
IL (1) IL173616A0 (es)
IS (1) IS8320A (es)
MX (1) MXPA06002017A (es)
NO (1) NO20060665L (es)
RU (1) RU2006108791A (es)
TW (1) TW200524911A (es)
UA (1) UA84712C2 (es)
WO (1) WO2005021537A1 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070053205A (ko) 2004-09-17 2007-05-23 에자이 알앤드디 매니지먼트 가부시키가이샤 의약 조성물
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
AU2006309551B2 (en) 2005-11-07 2012-04-19 Eisai R & D Management Co., Ltd. Use of combination of anti-angiogenic substance and c-kit kinase inhibitor
JP5583346B2 (ja) * 2006-01-18 2014-09-03 エルジー ハウスホールド アンド ヘルスケア リミテッド ｃ−Ｋｉｔ活性阻害剤、及び、肌美白剤
TW200740776A (en) * 2006-02-06 2007-11-01 Osi Pharm Inc N-phenylbenzotriazolyl c-kit inhibitors
EP2036557B1 (en) 2006-05-18 2015-10-21 Eisai R&D Management Co., Ltd. Antitumor agent for thyroid cancer
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US8962655B2 (en) 2007-01-29 2015-02-24 Eisai R&D Management Co., Ltd. Composition for treatment of undifferentiated gastric cancer
AU2008325608B2 (en) 2007-11-09 2013-03-14 Eisai R & D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
EP2400985A2 (en) 2009-02-25 2012-01-04 OSI Pharmaceuticals, LLC Combination of an either an anti-igf-1r antibody or an igf binding protein and a small molecule igf-1r kinase inhibitor
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en) 2009-02-27 2014-02-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
ES2573515T3 (es) 2010-06-25 2016-06-08 Eisai R&D Management Co., Ltd. Agente antitumoral que emplea compuestos con efecto inhibitorio de cinasas combinados
WO2012121168A1 (ja) * 2011-03-04 2012-09-13 国立大学法人京都大学 キナーゼ阻害剤
RU2580609C2 (ru) 2011-04-18 2016-04-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
EP2702173A1 (en) 2011-04-25 2014-03-05 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
ES2705950T3 (es) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarcadores para predecir y valorar la capacidad de respuesta de sujetos con cáncer de tiroides y de riñón a compuestos de lenvatinib
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20140179712A1 (en) 2012-12-21 2014-06-26 Astrazeneca Ab Pharmaceutical formulation of n-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2h-pyrazol-3-yl]-4-[(3r,5s)-3,5-dimethylpiperazin-1-yl]benzamide
EP2937337A4 (en) 2012-12-21 2016-06-22 Eisai R&D Man Co Ltd AMORPHIC FORM OF CHINOLINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF
AR094929A1 (es) 2013-02-28 2015-09-09 Bristol Myers Squibb Co Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
CN105102448B (zh) 2013-02-28 2018-03-06 百时美施贵宝公司 作为rock1和rock2抑制剂的苯基吡唑衍生物
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR096654A1 (es) 2013-06-20 2016-01-27 Ab Science Derivados de benzimidazol como inhibidores selectivos de proteína quinasa
TWI721954B (zh) 2014-08-28 2021-03-21 日商衛材R&D企管股份有限公司 高純度喹啉衍生物及其生產方法
RU2017128583A (ru) 2015-02-25 2019-03-25 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Способ ослабления горечи хинолинового производного
CA2978226A1 (en) 2015-03-04 2016-09-09 Merck Sharpe & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
AU2016279474B2 (en) 2015-06-16 2021-09-09 Eisai R&D Management Co., Ltd. Anticancer agent
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
GB8610980D0 (en) 1986-05-06 1986-06-11 Ici America Inc Heterocyclic fused tricyclic compounds
US5814651A (en) 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
CN1067386C (zh) 1994-02-10 2001-06-20 辉瑞大药厂 作为苯并二氮杂䓬受体位的兴奋剂和拮抗药的5－杂芳基吲哚衍生物
US5563143A (en) 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
US6001866A (en) 1995-10-05 1999-12-14 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5972980A (en) 1995-10-05 1999-10-26 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US6548524B2 (en) 1996-10-16 2003-04-15 American Cyanamid Company Preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and TACE inhibitors
EP0846689B1 (en) 1996-12-09 2004-01-14 Pfizer Inc. Benzimidazole compounds
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
BR9810456A (pt) 1997-06-27 2001-09-25 Fujisawa Pharmaceutical Co Composto de sulfonamida, método para sua obtenção e seu uso farmacêutico
US5990146A (en) * 1997-08-20 1999-11-23 Warner-Lambert Company Benzimidazoles for inhibiting protein tyrosine kinase mediated cellular proliferation
WO2000012089A1 (en) 1998-08-31 2000-03-09 Merck & Co., Inc. Novel angiogenesis inhibitors
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
US6465484B1 (en) 1997-09-26 2002-10-15 Merck & Co., Inc. Angiogenesis inhibitors
KR20010079546A (ko) 1998-07-28 2001-08-22 무라타 도시카즈 융합 헤테로환 디카르복실산 디아미드 유도체 또는 그의염, 제초제 및 그의 용도
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6329383B1 (en) 1999-01-25 2001-12-11 Pharmacia Ab 2-amino-5-pyrimidine acetic acid compounds
AU3931400A (en) 1999-04-02 2000-10-23 Neurogen Corporation N-benzimidazolylmethyl- and n-indolylmethyl-benzamides and their use as crf modulators
CO5190696A1 (es) 1999-06-16 2002-08-29 Smithkline Beecham Corp Antagonistas de los receptores il-8
US6534535B1 (en) 1999-08-12 2003-03-18 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
DE19939463A1 (de) 1999-08-20 2001-02-22 Boehringer Ingelheim Pharma Aminocarbonyl-substituierte Benzimidazolderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1085372B1 (en) 1999-09-13 2004-12-22 Eastman Kodak Company Photographic material having improved color reproduction
WO2001021634A1 (en) 1999-09-21 2001-03-29 Lion Bioscience Ag Benzimidazole derivatives and combinatorial libraries thereof
US6316474B1 (en) 1999-10-29 2001-11-13 Merck & Co., Inc. 2-benzyl and 2-heteroaryl benzimidazole NMDA/NR2B antagonists
EP1263754A1 (en) 2000-02-01 2002-12-11 Millennium Pharmaceuticals, Inc. INDALONE AND BENZIMIDAZOLONE INHIBITORS OF FACTOR Xa
US20020072530A1 (en) 2000-02-01 2002-06-13 Bing-Yan Zhu Indole and benzimidazole inhibitors of factor Xa
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
AU2002216314A1 (en) 2000-10-12 2002-04-22 Scott A Henderson Heterocyclic angiogenesis inhibitors
IL156304A0 (en) 2000-12-11 2004-01-04 Tularik Inc Cxcr3 antagonists
GB0102109D0 (en) 2001-01-26 2001-03-14 Syngenta Ltd Chemical process
WO2002069965A1 (en) 2001-03-05 2002-09-12 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
DE60221804T2 (de) * 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
WO2002076960A1 (en) 2001-03-22 2002-10-03 Abbott Gmbh & Co. Kg Transition metal mediated process

Also Published As

Publication number Publication date
CN1839130A (zh) 2006-09-27
EP1664032B1 (en) 2008-11-05
AU2004268948A1 (en) 2005-03-10
WO2005021537A1 (en) 2005-03-10
JP2007502820A (ja) 2007-02-15
DE602004017623D1 (de) 2008-12-18
RU2006108791A (ru) 2006-07-27
EP1664032A1 (en) 2006-06-07
NO20060665L (no) 2006-05-16
TW200524911A (en) 2005-08-01
UA84712C2 (en) 2008-11-25
ATE413395T1 (de) 2008-11-15
IS8320A (is) 2006-02-21
MXPA06002017A (es) 2006-05-31
BRPI0413785A (pt) 2006-11-07
KR20060115346A (ko) 2006-11-08
CA2536151A1 (en) 2005-03-10
JP4795237B2 (ja) 2011-10-19
AP2006003553A0 (en) 2006-04-30
IL173616A0 (en) 2006-07-05

Similar Documents

Publication Publication Date Title
AR045389A1 (es) Inhibidores del c-kit con estructura de pirazolil-amidil-benzoimidazolilo n-sustituido
PE20080318A1 (es) Derivados de diceto-piperazina y piperidina como agentes antivirales
PE20191532A1 (es) Compuestos heterociclicos como inmunomoduladores
PE20220931A1 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
AR059338A1 (es) N-fenilbenzotriazolilo como inhibidores de c-kit
CA2672373A1 (en) Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
PE20141681A1 (es) Inhibidores de btk
AR057109A1 (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis
PE20210414A1 (es) Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
AR052330A1 (es) Derivados de adamantano que comprenden quinoleinas sustituidas
AR052419A1 (es) Derivados de bencimidazolil n-sustituidos,inhibidores del protooncogen c-kit
PE20131377A1 (es) Triazina-oxadiazoles
PE20030062A1 (es) Derivados aralquilsulfonil-3-(pirrol-2-ilmetiliden)-2-indolinona como inhibidores de quinasas
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR080865A1 (es) Derivados de espirotetrahidronaftaleno, composiciones farmaceuticas que los contienen, proceso de preparacion y uso de los mismos para tratar enfermedades neurodegenerativas,tal como alzheimer.
ME01089B (me) Derivat benzimidazola i njegova upotreba kao antagonista receptora aii
AR046711A1 (es) 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones
IL272762B2 (en) Compressed heterocyclics as BCL-2 inhibitors for the treatment of neoplastic diseases
AR049956A1 (es) DERIVADOS DE 1,3 - OXAZOLIDIN - 2 - ONA COMO INHIBIDORES DE CETP Y ELEVADORES DEL NIVEL DE LAD-C; COMPOSICIONES FARMACÉUTICAS QUE LOS CONTIENEN Y SU USO EN LA FABRICACIoN DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LA ATEROSCLEROSIS.
AR046297A1 (es) Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo
ATE476431T1 (de) Piperidin- und azetidinderivate als glyt1- inhibitoren
AR067327A1 (es) Derivados de piperidina / piperazina
PE20141067A1 (es) Compuestos para el tratamiento de la adiccion
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal